Sophiris Bio Priced, Nasdaq: SPHS
Developing a biologic to treat enlarged prostates.
Industry: Health Care
First Day Return: -17.0%
SPHS
Developing a biologic to treat enlarged prostates.
| IPO Data | |
|---|---|
| IPO Date | 08/16/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $65 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | La Jolla, CA, United States |
| Founded | 2002 |
| Employees at IPO | 10 |
| Website www.sophirisbio.com | |
IPO News for Sophiris Bio
Sophiris Bio (SPHS) Performance
